Official start of the TI Pharma project D2-102

We are happy to announce the official start of the project D2-102 “Metabolic stability assessment as a new tool in the hit-to-lead selection process and the generation of new lead compound libraries”.

The aim of the project is to come to innovative and state-of the art validated analytical technologies to assess the metabolic instability and its mechanism of action for hit-to-lead test compounds, the chemical identity of the formed metabolites, their potency towards the target of interest combined with novel production methods of the metabolites and other NCE’s based on humanized BM3 cell mutants.

Team members in this TI-Pharma project are N.V. Organon, Stichting Katholieke Universiteit Nijmegen, the Free University of Amsterdam and Xendo Drug Development

Top Institute Pharma

Top Institute Pharma (TI Pharma) aims to achieve leadership in research and education in areas that are critical for the international competitive position of the pharmaceutical industry.

The Institute conducts groundbreaking, cross-disciplinary research and offers advanced training programs focused on improving the efficiency of the entire process of drug discovery and development. This will eventually reduce the 'time- & cost-to-patient' of new medicines and contribute to the well-being of society. TI Pharma devotes special attention to the Priority Medicines project of the World Health Organization. For more information see www.tipharma.com.